A Phase 2 interventional study of tipranavir and ritonavir in HIV Infections, sponsored by Boehringer Ingelheim. Completed at 12 sites in 3 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-06-06.
Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing tipranavir in HIV Infections — none open to participants now, none under way, none of them phase 3. tipranavir · HIV Infections.
Among the 16 studies testing tipranavir in HIV Infections, this one is the 9th largest by enrollment, is one of 5 that started in 2007, is one of 4 in phase 2, and was the 12th registered.
4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.
Browse HIV Infections studies →None of the 16 studies testing tipranavir in HIV Infections is open now. The open studies under HIV Infections, anywhere →
tipranavir: first FDA approval 2005 (APTIVUS), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 7 · Phase 4 1
First in 1999; this study’s year is marked. 5 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 85 is close to the median of 80 across 3,491 interventional studies indexed under HIV Infections.
Median enrollment 151 across the 16 interventional studies. Of the 16 that completed or were terminated, 8 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 16 have an industry lead sponsor. The 5 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
67 studies in HIV Infections by Boehringer Ingelheim: none open now, none under way, none of them phase 3. Of 62 finished, 24 (39%) have results posted.
Among the 67 studies in HIV Infections by Boehringer Ingelheim, this one is the 22nd largest by enrollment of the 46 interventional ones that give a count, is one of 9 that started in 2007, is one of 12 in phase 2, and was the 29th registered.
Boehringer Ingelheim’s HIV Infections studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 16 studies testing tipranavir in HIV Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Boehringer Ingelheim’s 67 in HIV Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to identify an optimal dose combination(s) of tipranavir (TPV) and ritonavir (RTV) for antiretroviral treatment naïve HIV-1 infected patients that can be used in pivotal trial by assessing the steady-state pharmacokinetics and short-term efficacy and safety
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Willingness to abstain from the following starting 2 weeks prior to administration of any study medication and up until the end of the study:
o Grapefruit or grapefruit juice, Seville oranges, St. John's Wort, and Milk Thistle.
Willingness to abstain from the following starting 3 days prior to PK sampling:
o Garlic supplements and methylxanthine containing foods or drinks (including coffee, tea, cola, energy drinks, chocolate, etc.).
Exclusion Criteria:
Female patients of who:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Viral Load (log10 Copies/mL) Change From Baseline (Last Observation Carried Forward (LOCF))
Time frame: Baseline (Day 0) to Final (Day 14)
Apparent Oral Clearance I(Cl/F) of Tipranavir
Tipranavir pharmacokinetics - Clearance (CL) is defined as the dose of a drug divided by the area-under-the-concentration-time curve (AUC), ie. CL = Dose / AUC. For extravascu-lar models the fraction of dose absorbed cannot be estimated, therefore "clear-ance" for these models is actually Cl/F where F is the fraction of the drug dose which is absorbed.
Time frame: Final (Day 14)
Area Under the Curve(AUC) of Tipranavir 24 h for Once Daily (QD) and AUC 12 h for Twice Daily (BID)
Tipranavir (TPV) pharmacokinetics
Time frame: Final (Day 13 for QD, Day 14 for BID)
Concentration-24 Hour (hr) Post Dose of Tipranavir - (Cp 24 h for QD and 12 hr Post Dose (CP 12h) for BID
TPV pharmacokinetics
Time frame: Final (Day 13 for QD, Day 14 for BID)
Trough Concentration (Cmin) of Tipranavir
TPV pharmacokinetics
Time frame: Final (Day 13 for QD, Day 14 for BID)
Maximum Concentration (Cmax) of Tipranavir
TPV pharmacokinetics
Time frame: Final (Day 13 for QD, Day 14 for BID)
Volume of Distribution (V/F) of Tipranavir
Tipranavir pharmacokinetics
Time frame: Final (Day 14)
Terminal Half-Life (t1/2) of Tipranavir
Tipranavir pharmacokinetics
Time frame: Final (Day 14)
Time to Cmax (Tmax) of Tipranavir
Tipranavir pharmacokinetics
Time frame: Final (Day 14)
AUC 24 of Ritonavir for QD and AUC 12 of Ritonavir for BID
Ritonavir pharmacokinetics
Time frame: Final (Day 13 for QD, Day 14 for BID)
Cp 24 h of Ritonavir for QD and CP 12 h of Ritonavir for BID
Ritonavir pharmacokinetics
Time frame: Final (Day 13 for QD, Day 14 for BID)
Apparent Oral Clearance I(Cl/F) of Ritonavir
Ritonavir pharmacokinetics
Time frame: Final (Day 13 for QD, Day 14 for BID)
Volume of Distribution (V/F) of Ritonavir
Ritonavir pharmacokinetics
Time frame: Final (Day 14)
Terminal Half-Life (t1/2) of Ritonavir
Ritonavir pharmacokinetics
Time frame: Final (Day 14)
Tmax of Ritonavir
Ritonavir pharmacokinetics
Time frame: Final (Day 14)
Cmax of Ritonavir
Ritonavir pharmacokinetics
Time frame: Visits baseline, 5, 7, 9 and 13 or 14
Clinical Abnormal Findings in Laboratory and Physical Examination
Time frame: Screening through the end of the study (14 days)
| Milestone | Tipranavir With Ritonavir (TPV/r) 500/200 mg Once Daily | Tipranavir With Ritonavir (TPV/r) 250/100 mg Twice Daily | Tipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily |
|---|---|---|---|
| Started | 30 | 27 | 28 |
| Completed | 30 | 25 | 24 |
| Not completed | 0 | 2 | 4 |
| Withdrew: Randomized but not treated | 0 | 2 | 0 |
| Withdrew: Adverse event | 0 | 0 | 3 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
| Log10 copies/mL | Tipranavir With Ritonavir (TPV/r) 500/200 mg Once Daily | Tipranavir With Ritonavir (TPV/r) 250/100 mg Twice Daily | Tipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily |
|---|---|---|---|
| Viral Load (log10 Copies/mL) Change From Baseline (Last Observation Carried Forward (LOCF)) | -1.43 (-1.66 to -1.24) | -1.55 (-1.70 to -1.37) | -1.47 (-1.66 to -1.09) |
Tipranavir pharmacokinetics - Clearance (CL) is defined as the dose of a drug divided by the area-under-the-concentration-time curve (AUC), ie. CL = Dose / AUC. For extravascu-lar models the fraction of dose absorbed cannot be estimated, therefore "clear-ance" for these models is actually Cl/F where F is the fraction of the drug dose which is absorbed.
| L/h | Tipranavir With Ritonavir (TPV/r) 500/200 mg Once Daily | Tipranavir With Ritonavir (TPV/r) 250/100 mg Twice Daily | Tipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily |
|---|---|---|---|
| Apparent Oral Clearance I(Cl/F) of Tipranavir | 1.45 ± 26.79 | 1.43 ± 26.77 | 1.57 ± 35.40 |
Tipranavir (TPV) pharmacokinetics
| h*uM | Tipranavir With Ritonavir (TPV/r) 500/200 mg Once Daily | Tipranavir With Ritonavir (TPV/r) 250/100 mg Twice Daily | Tipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily |
|---|---|---|---|
| Area Under the Curve(AUC) of Tipranavir 24 h for Once Daily (QD) and AUC 12 h for Twice Daily (BID) | 571.3 ± 27.3 | 289.3 ± 26.8 | 538.2 ± 36.4 |
TPV pharmacokinetics
| uM | Tipranavir With Ritonavir (TPV/r) 500/200 mg Once Daily | Tipranavir With Ritonavir (TPV/r) 250/100 mg Twice Daily | Tipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily |
|---|---|---|---|
| Concentration-24 Hour (hr) Post Dose of Tipranavir - (Cp 24 h for QD and 12 hr Post Dose (CP 12h) for BID | 3.26 ± 92.4 | 10.27 ± 49.4 | 17.75 ± 71.7 |
TPV pharmacokinetics
| uM | Tipranavir With Ritonavir (TPV/r) 500/200 mg Once Daily | Tipranavir With Ritonavir (TPV/r) 250/100 mg Twice Daily | Tipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily |
|---|---|---|---|
| Trough Concentration (Cmin) of Tipranavir | 2.8 ± 106.8 | 12.73 ± 53.1 | 21.26 ± 86.8 |
TPV pharmacokinetics
| uM | Tipranavir With Ritonavir (TPV/r) 500/200 mg Once Daily | Tipranavir With Ritonavir (TPV/r) 250/100 mg Twice Daily | Tipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily |
|---|---|---|---|
| Maximum Concentration (Cmax) of Tipranavir | 54.64 ± 20.2 | 36.98 ± 19.9 | 69.66 ± 26.5 |
Tipranavir pharmacokinetics
| L | Tipranavir With Ritonavir (TPV/r) 500/200 mg Once Daily | Tipranavir With Ritonavir (TPV/r) 250/100 mg Twice Daily | Tipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily |
|---|---|---|---|
| Volume of Distribution (V/F) of Tipranavir | 10.02 ± 14.33 | 9.33 ± 9.17 | 9.39 ± 12.34 |
Tipranavir pharmacokinetics
| h | Tipranavir With Ritonavir (TPV/r) 500/200 mg Once Daily | Tipranavir With Ritonavir (TPV/r) 250/100 mg Twice Daily | Tipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily |
|---|---|---|---|
| Terminal Half-Life (t1/2) of Tipranavir | 4.79 ± 26.3 | 4.51 ± 22.4 | 4.14 ± 33.6 |
Tipranavir pharmacokinetics
| h | Tipranavir With Ritonavir (TPV/r) 500/200 mg Once Daily | Tipranavir With Ritonavir (TPV/r) 250/100 mg Twice Daily | Tipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily |
|---|---|---|---|
| Time to Cmax (Tmax) of Tipranavir | 3.07 ± 14.7 | 2.34 ± 15.2 | 2.38 ± 16.6 |
Ritonavir pharmacokinetics
| h*uM | Tipranavir With Ritonavir (TPV/r) 500/200 mg Once Daily | Tipranavir With Ritonavir (TPV/r) 250/100 mg Twice Daily | Tipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily |
|---|---|---|---|
| AUC 24 of Ritonavir for QD and AUC 12 of Ritonavir for BID | 5.05 ± 44.0 | 2.25 ± 47.0 | 1.74 ± 48.9 |
Ritonavir pharmacokinetics
| uM | Tipranavir With Ritonavir (TPV/r) 500/200 mg Once Daily | Tipranavir With Ritonavir (TPV/r) 250/100 mg Twice Daily | Tipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily |
|---|---|---|---|
| Cp 24 h of Ritonavir for QD and CP 12 h of Ritonavir for BID | 0.005 ± 206.2 | 0.039 ± 134.0 | 0.025 ± 129.9 |
Ritonavir pharmacokinetics
| L/h | Tipranavir With Ritonavir (TPV/r) 500/200 mg Once Daily | Tipranavir With Ritonavir (TPV/r) 250/100 mg Twice Daily | Tipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily |
|---|---|---|---|
| Apparent Oral Clearance I(Cl/F) of Ritonavir | 39.6 ± 44.0 | 44.4 ± 47.0 | 57.4 ± 48.9 |
Ritonavir pharmacokinetics
| L | Tipranavir With Ritonavir (TPV/r) 500/200 mg Once Daily | Tipranavir With Ritonavir (TPV/r) 250/100 mg Twice Daily | Tipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily |
|---|---|---|---|
| Volume of Distribution (V/F) of Ritonavir | 97.5 ± 26.8 | 90.8 ± 24.7 | 88.9 ± 28.7 |
Ritonavir pharmacokinetics
| Hours | Tipranavir With Ritonavir (TPV/r) 500/200 mg Once Daily | Tipranavir With Ritonavir (TPV/r) 250/100 mg Twice Daily | Tipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily |
|---|---|---|---|
| Terminal Half-Life (t1/2) of Ritonavir | 1.71 ± 45.5 | 1.42 ± 59.5 | 1.07 ± 56.1 |
Ritonavir pharmacokinetics
| h | Tipranavir With Ritonavir (TPV/r) 500/200 mg Once Daily | Tipranavir With Ritonavir (TPV/r) 250/100 mg Twice Daily | Tipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily |
|---|---|---|---|
| Tmax of Ritonavir | 2.84 ± 23.9 | 2.33 ± 24.9 | 2.05 ± 28.8 |
Ritonavir pharmacokinetics
| uM | Tipranavir With Ritonavir (TPV/r) 500/200 mg Once Daily | Tipranavir With Ritonavir (TPV/r) 250/100 mg Twice Daily | Tipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily |
|---|---|---|---|
| Cmax of Ritonavir | 0.632 ± 32.5 | 0.346 ± 30.7 | 0.291 ± 34.7 |
| participants | Tipranavir With Ritonavir (TPV/r) 500/200 mg Once Daily | Tipranavir With Ritonavir (TPV/r) 250/100 mg Twice Daily | Tipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily |
|---|---|---|---|
| Alanine aminotransferase (ALT) increased | 0 | 0 | 1 |
| Aspartate aminotransferase (AST) increased | 0 | 0 | 1 |
Collected over 14 days, from first treatment until last treatment. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tipranavir With Ritonavir (TPV/r) 500/200 mg Once Daily | — | 0/30 (0%) | 17/30 (56.7%) |
| Tipranavir With Ritonavir (TPV/r) 250/100 mg Twice Daily | — | 0/25 (0%) | 9/25 (36%) |
| Tipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily | — | 1/28 (3.6%) | 15/28 (53.6%) |
| Event | Tipranavir With Ritonavir (TPV/r) 500/200 mg Once Daily | Tipranavir With Ritonavir (TPV/r) 250/100 mg Twice Daily | Tipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily |
|---|---|---|---|
| Alanine aminotransferase increasedInvestigations | 0/30 | 0/25 | 1/28 |
| Aspartate aminotransferase increasetInvestigations | 0/30 | 0/25 | 1/28 |
| Event | Tipranavir With Ritonavir (TPV/r) 500/200 mg Once Daily | Tipranavir With Ritonavir (TPV/r) 250/100 mg Twice Daily | Tipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 10/30 | 3/25 | 11/28 |
| NauseaGastrointestinal disorders | 3/30 | 1/25 | 4/28 |
| HeadacheNervous system disorders | 2/30 | 2/25 | 4/28 |
| FatigueGeneral disorders | 1/30 | 3/25 | 2/28 |
| Abdominal pain upperGastrointestinal disorders | 3/30 | 1/25 | 1/28 |
| FlatulenceGastrointestinal disorders | 0/30 | 2/25 | 0/28 |
| DizzinessNervous system disorders | 2/30 | 1/25 | 2/28 |
| DysgeusiaNervous system disorders | 2/30 | 0/25 | 0/28 |
| InsomniaPsychiatric disorders | 2/30 | 0/25 | 0/28 |
Treated Set, includes all patients that were randomized and were documented to have received at least one dose of investigational treatment
| Age, Continuous(years) | Tipranavir With Ritonavir (TPV/r) 500/200 mg Once Daily | Tipranavir With Ritonavir (TPV/r) 250/100 mg Twice Daily | Tipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily | Total |
|---|---|---|---|---|
| Mean | 33 ± 7.54 | 36.9 ± 8.04 | 36.4 ± 8 | 35.3 ± 7.94 |
| Sex: Female, Male(Participants) | Tipranavir With Ritonavir (TPV/r) 500/200 mg Once Daily | Tipranavir With Ritonavir (TPV/r) 250/100 mg Twice Daily | Tipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily | Total |
|---|---|---|---|---|
| Female | 2 | 1 | 4 | 7 |
| Male | 28 | 24 | 24 | 76 |
The record gives a start of Oct 2007 and a primary completion of May 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2009, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tipranavir · Ritonavir